Abstract:Background: Anti-tuberculosis drug-induced liver injury (ATB-DILI) is an adverse reaction with a high incidence and the greatest impact on tuberculosis treatment. However, there is a lack of effective biomarkers for the early prediction of ATB-DILI. Herein, this study uses UPLC‒MS/MS to reveal the plasma metabolic profile and lipid profile of ATB-DILI patients before drug administration and screen new biomarkers for predicting ATB-DILI.Methods: A total of 60 TB patients were enrolled, and plasma was collected before antituberculosis drug administration. The untargeted metabolomics and lipidomics analyses were performed using UPLC‒MS/MS, and the high-resolution mass spectrometer Q Exactive was used for data acquisition in both positive and negative ion modes. The random forest package of R software was used for data screening and model building.Results: A total of 60 TB patients, including 30 ATB-DILI patients and 30 non-ATB-DILI subjects, were enrolled. There were no significant differences between the ATB-DILI and control groups in age, sex, smoking, drinking or body mass index (p > 0.05). Twenty-two differential metabolites were selected. According to KEGG pathway analysis, 9 significantly enriched metabolic pathways were found, and both drug metabolism-other enzymes and niacin and nicotinamide metabolic pathways were found in both positive and negative ion models. A total of 7 differential lipid molecules were identified between the two groups. Ferroptosis and biosynthesis of unsaturated fatty acids were involved in the occurrence of ATB-DILI. Random forest analysis showed that the model built with the top 30 important variables had an area under the ROC curve of 0.79 (0.65–0.93) for the training set and 0.79 (0.55–1.00) for the validation set.Conclusion: This study demonstrated that potential markers for the early prediction of ATB-DILI can be found through plasma metabolomics and lipidomics. The random forest model showed good clinical predictive value for ATB-DILI.

Endogenous Peroxynitrite Activated Fluorescent Probe for Revealing Anti‐tuberculosis Drug Induced Hepatotoxicity

Peroxynitrite imaging in ferroptosis-mediated drug-induced liver injury with a near-infrared fluorescence probe

Peroxynitrite Activatable NIR-II Fluorescent Molecular Probe for Drug-Induced Hepatotoxicity Monitoring.

A Highly Sensitive and Selective Near-Infrared Fluorescent Probe for Imaging Peroxynitrite in Living Cells and Drug-Induced Liver Injury Mice

Real-time Monitoring and Accurate Diagnosis of Drug-Induced Hepatotoxicity in Vivo by Ratio-Fluorescence and Photoacoustic Imaging of Peroxynitrite

Endoplasmic reticulum-targeted fluorescent probe with aggregation-induced emission features for imaging peroxynitrite in drug-induced liver injury model

A hepatocyte-targeting near-infrared ratiometric fluorescent probe for monitoring peroxynitrite during drug-induced hepatotoxicity and its remediation.

Quasi-LD-Targeted and ONOO--Responsive Fluorescent Probe for Investigating the Interaction of Nonalcoholic Fatty Liver with Drug- Induced Liver Injury

Rational Construction of a Novel Fluorescent Probe for Imaging Peroxynitrite in the Endoplasmic Reticulum During Drug-Induced Liver Injury

Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs

Selective FRET nano probe based on carbon dots and naphthalimide–isatin for the ratiometric detection of peroxynitrite in drug-induced liver injury

NIR-excited imaging of drug-induced liver injury using a superoxide-activated ratiometric upconversion luminescence nanoprobe

A novel hepatocyte-targeting ratiometric fluorescent probe for imaging hydrogen peroxide in zebrafish

Activatable photoacoustic/fluorescent dual-modal probe for monitoring of drug-induced liver hypoxia in vivo

Accurate imaging in the processes of formation and inhibition of drug-induced liver injury by an activable fluorescent probe for ONOO−

A hemicyanine-modified upconversion nanoprobe for NIR-excited evaluating superoxide signaling in drug-induced liver injury

Plasma Metabolomic and Lipidomic Alterations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Pyrazinamide related prolonged drug-induced liver injury: A case report

A near‐infrared fluorescent probe for detecting hydrazine metabolized from isoniazid in living cells

Longitudinal metabolomics of human plasma reveal metabolic dynamics and predictive markers of antituberculosis drug-induced liver injury

Screening and Optimization of a Water-Soluble Near-Infrared Fluorescent Probe for Drug-Induced Liver Injury Monitoring.